Kari M Morrissey

Years Active: 2019-2020
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Patrick Y Wen, Timothy F Cloughesy, Alan G Olivero, Kari M Morrissey, Timothy R Wilson, Xuyang Lu, Lars U Mueller, Alexandre F Coimbra, Benjamin M Ellingson, Elizabeth Gerstner, Eudocia Q Lee, Jordi Rodon
First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (8) (2020)
Kari M Morrissey, Mathilde Marchand, Hina Patel, Rong Zhang, Benjamin Wu, H Phyllis Chan, Almut Mecke, Sandhya Girish, Jin Y Jin, Helen R Winter, René Bruno
Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer chemotherapy and pharmacology 84 (6) (2019)
Shuguang Ma, Julia Suchomel, Evelyn Yanez, Edward Yost, Xiaorong Liang, Rui Zhu, Hoa Le, Nicholas Siebers, Lori Joas, Roland Morley, Stephanie Royer-Joo, Andrea Pirzkall, Laurent Salphati, Joseph A Ware, Kari M Morrissey
Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor. British journal of clinical pharmacology 85 (8) (2019)

Kari M Morrissey.css-eqlu8i{font-size:small;padding-left:4px;}